Method for producing biomaterials, method for treating scaffolds, treatment liquid and aqueous solution

Treating scaffolds with a hydroxyl group-containing polymer and recellularization addresses biocompatibility issues in biomaterials derived from decellularized extracellular matrices, resulting in improved transplantation compatibility.

JP7582610B2Active Publication Date: 2024-11-13NIPPON SHOKUBAI CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020115054
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-07-02
Publication Date
2024-11-13
Estimated Expiration
2040-07-02

AI Technical Summary

Technical Problem

Biomaterials derived from decellularized extracellular matrices face issues with biocompatibility, leading to thrombus formation and occlusion of blood vessels during transplantation.

Method used

A method involving treatment of scaffolds containing decellularized extracellular matrices with a hydroxyl group-containing polymer, followed by recellularization, to enhance biocompatibility and antithrombotic properties.

Benefits of technology

The method results in biomaterials with improved biocompatibility and reduced thrombus formation, enhancing their suitability for transplantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582610000001
    Figure 0007582610000001
  • Figure 0007582610000002
    Figure 0007582610000002
  • Figure 0007582610000003
    Figure 0007582610000003
Patent Text Reader

Abstract

To provide a method for producing a biological material with improved biocompatibility.SOLUTION: A method for producing a biological material includes the step of treating a scaffold including a decellularized extracellular matrix with a hydroxy group-containing polymer having a group represented by the formula (I). *-O-Z (I) (in the formula (I), Z is a monovalent group in which two or more hydrogen atoms of a C3-8 monovalent hydrocarbon group are substituted with a hydroxy group, and * is a bond position of the monovalent group).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a biomaterial, a method for treating a scaffold, a treatment liquid and an aqueous solution. [Background technology]

[0002] In recent years, extracellular matrices derived from decellularized animal tissues, i.e., decellularized extracellular matrices, have been attracting attention as biomaterials. Since decellularized extracellular matrices are materials derived from living organisms, they are less likely to cause rejection in the body, and research and commercialization of such matrices as adhesion inhibitors, transplant materials for various organs or blood vessels, etc., has been progressing (Patent Documents 1 to 3). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Special Publication No. 2013-536738 [Patent Document 2] JP 2016-144470 A [Patent Document 3] International Publication No. 2018 / 186502 Summary of the Invention [Problem to be solved by the invention]

[0004] However, as a result of intensive research by the present inventors, it was found that there is still room for improvement in terms of biocompatibility of biomaterials using decellularized extracellular matrix; for example, when a material obtained by culturing endothelial cells and fibroblasts using the decellularized extracellular matrix as a scaffold is transplanted into a living body, blood perfusion causes blood clots and blood vessel blockage.

[0005] The present invention has been made in view of the above circumstances, and aims to provide a method for producing a biomaterial with improved biocompatibility, or a method for treating a scaffold to improve the biocompatibility. Another aim of the present invention is to provide a treatment liquid or aqueous solution that can improve the biocompatibility of a biomaterial. [Means for solving the problem]

[0006] The method for producing a biomaterial of the present invention comprises the step of treating a scaffold containing a decellularized extracellular matrix with a hydroxyl-containing polymer having a group represented by the following formula (I): *-OZ···(I) (In formula (I), Z is a monovalent group in which two or more hydrogen atoms of a monovalent hydrocarbon group having 3 to 8 carbon atoms have been substituted with hydroxyl groups, and * represents the bonding position of the monovalent group.)

[0007] Preferably, the scaffold comprises cells engrafted onto the decellularized extracellular matrix.

[0008] The method for producing a biomaterial of the present invention preferably further comprises the step of recellularizing the treated scaffold.

[0009] The decellularized extracellular matrix is ​​preferably derived from an organ or blood vessel.

[0010] The decellularized extracellular matrix is ​​preferably derived from the liver or a part of the liver.

[0011] The hydroxyl-containing polymer preferably contains a structural unit derived from a monomer having a group represented by formula (I) and an ethylenically unsaturated group.

[0012] In the method for producing a biomaterial of the present invention, it is preferable to carry out the treatment with a solution containing the above-mentioned hydroxyl group-containing polymer.

[0013] In the method for producing a biomaterial of the present invention, it is preferable that the decellularized extracellular matrix has a portion derived from a blood vessel, and the treatment is carried out by injecting the solution into the lumen of the portion derived from the blood vessel, or by circulating the solution within the lumen of the portion derived from the blood vessel.

[0014] The method for treating a scaffold of the present invention comprises the step of treating a scaffold containing a decellularized extracellular matrix with a hydroxyl-containing polymer having a group represented by the following formula (I): *-OZ···(I) (In formula (I), Z is a monovalent group in which two or more hydrogen atoms of a monovalent hydrocarbon group having 3 to 8 carbon atoms have been substituted with hydroxyl groups, and * represents the bonding position of the monovalent group.)

[0015] The treatment solution of the present invention is a treatment solution for treating a scaffold containing a decellularized extracellular matrix, and contains a hydroxyl-containing polymer having a group represented by the following formula (I): *-OZ···(I) (In formula (I), Z is a monovalent group in which two or more hydrogen atoms of a monovalent hydrocarbon group having 3 to 8 carbon atoms have been substituted with hydroxyl groups, and * represents the bonding position of the monovalent group.)

[0016] The aqueous solution of the present invention contains a hydroxyl-containing polymer having a group represented by the following formula (I) and a buffering agent. *-OZ···(I) (In formula (I), Z is a monovalent group in which two or more hydrogen atoms of a monovalent hydrocarbon group having 3 to 8 carbon atoms have been substituted with hydroxyl groups, and * represents the bonding position of the monovalent group.) Effect of the Invention

[0017] According to the present invention, it is possible to provide a method for producing a biomaterial with improved biocompatibility, or a method for treating a scaffold to improve the biocompatibility. Also, according to the present invention, it is possible to provide a treatment liquid or aqueous solution that can improve the biocompatibility of a biomaterial. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The method for producing a biomaterial of this embodiment includes a step of treating a scaffold containing a decellularized extracellular matrix with a hydroxyl-containing polymer having a group represented by the following formula (I): The method for producing a biomaterial of this embodiment is carried out outside the body (i.e., ex vivo or in vitro). *-OZ···(I) (In formula (I), Z is a monovalent group in which two or more hydrogen atoms of a monovalent hydrocarbon group having 3 to 8 carbon atoms have been substituted with hydroxyl groups, and * represents the bonding position of the monovalent group.) According to such a production method, it is possible to provide a biomaterial having superior biocompatibility, and in particular, it is likely to be possible to provide a biomaterial having superior antithrombotic properties.

[0019] In the following, the decellularized extracellular matrix may be referred to as decellularized ECM, and the hydroxyl-containing polymer having a group represented by the above formula (I) may be referred to as the hydroxyl-containing polymer (I).

[0020] <Decellularized ECM> The scaffold of this embodiment is a material for engrafting and culturing cells, and includes a decellularized extracellular matrix. The decellularized ECM is an extracellular matrix remaining after removing living cells from a tissue or organ derived from a living body (i.e., decellularization). The animal is preferably a mammal, such as a human, rat, mouse, guinea pig, marmoset, rabbit, dog, cat, sheep, pig, horse, cow, goat, monkey, chimpanzee, etc., and may be an immunodeficient animal.

[0021] The decellularized ECM may be derived from an animal organ or tissue, specifically, from an animal's internal organ, blood vessel, or skin (or dermis). Organs include the heart, intestine, trachea, lung, liver, kidney, stomach, pancreas, esophagus, etc. The decellularized ECM may be derived from a part of these organs, or from the whole of them.

[0022] Examples of blood vessels include veins, arteries, portal veins, and capillaries.

[0023] The method for producing decellularized ECM is not particularly limited and can be appropriately selected depending on the organ or tissue, animal species, etc. used. Specific examples include cell membrane destruction by mechanical stimuli such as high pressure, freezing, electroporation, and osmotic pressure change, washing and cell destruction with a decellularization solution, etc. These methods may be used alone or in combination. When used in combination, for example, a method in which an animal's organ or tissue is frozen and then thawed to destroy the cell membrane of the cells contained in the organ or tissue, and the organ or tissue is perfused with a decellularization solution to further destroy and wash away the cells, can be mentioned.

[0024] The temperature at which the organ or tissue is frozen may be, for example, -10°C or lower, -20°C or lower, -30°C or lower, -40°C or lower, -50°C or lower, -60°C or lower, -70°C or lower, -80°C or lower, -90°C or lower, or -100°C or lower. The temperature at which the organ or tissue is frozen may be, for example, -150°C to -10°C, -130°C to -15°C, or -100°C to -20°C. The temperature at which the frozen organ or tissue is thawed may be, for example, 4°C to 50°C, 4°C to 45°C, or 4°C to 40°C.

[0025] Examples of the decellularization solution include aqueous solutions in which a surfactant, an acidic compound, an alkaline compound, an enzyme, a chelating agent, or an alcohol is dissolved in water, physiological saline, or the like. As the surfactant, either an ionic surfactant or a nonionic surfactant may be used, or these may be used in combination. Examples of the ionic surfactant include anionic surfactants such as sodium dodecyl sulfate (SDS), deoxycholate, cholate, sarkosyl, and Triton (registered trademark) X-200, and zwitterionic surfactants such as 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS). Examples of the nonionic surfactant include Triton (registered trademark) X-100, n-dodecyl-β-D-maltoside (DDM), digitonin, Tween (registered trademark) 20, and Tween (registered trademark) 80. After perfusion, the obtained decellularized ECM may be washed with water or physiological saline to wash away the decellularization solution. Examples of the enzyme include nucleases such as DNase and RNase, protease such as trypsin and collagenase, and α-galactosidase.

[0026] The decellularized ECM may be protein cross-linked. If the decellularized ECM is protein cross-linked, the mechanical strength of the decellularized ECM is improved, which is preferable. The protein cross-linking may be a treatment with an external cross-linking agent that bonds with two or more protein molecules to cross-link the protein molecules. The protein cross-linking may also be a treatment in which protein molecules are reacted with each other to form bonds such as disulfide bonds between amino acid residues contained in the protein molecules to directly cross-link them.

[0027] The scaffold may contain cells engrafted on the decellularized ECM. That is, the decellularized ECM contained in the scaffold may be recellularized in advance before being treated with the hydroxyl group-containing polymer (I). Examples of cells engrafted on the decellularized ECM include endothelial cells, epithelial cells, fibroblasts, parenchymal cells, and the like. In particular, when the decellularized ECM is derived from the liver or a part of the liver, examples of cells that form liver tissue include vascular endothelial cells, bile duct epithelial cells, hepatic parenchymal cells, hepatic progenitor cells, Kupffer cells, similar endothelial cells, stellate cells, and the like. The method of recellularization is not particularly limited, and examples thereof include the following methods. First, gamma-ray sterilized decellularized ECM is enclosed in a closed chamber, and the circulatory circuit is connected to the vein and portal vein. While circulating the cell culture medium, various cells (liver parenchymal cells, vascular endothelial cells, etc.) are loaded from the blood vessels into the decellularized ECM according to a specific order, injection speed, and injection pressure. After several days of circulatory culture, the various cells form an orderly three-dimensional structure and attach to the decellularized ECM, resulting in recellularization.

[0028] The scaffold of this embodiment may contain components other than the decellularized ECM. Examples of such components include hydrogel. When the scaffold contains hydrogel, the mechanical stability of the scaffold is increased, and the shape of the scaffold is easily maintained even after it is implanted in a living body.

[0029] A hydrogel is a gel containing water and a polymer. The polymer is not limited as long as it is a biocompatible polymer, and may be crosslinked or uncrosslinked. Specifically, examples of the polymer include hydrophilic polymers such as polyacrylamide, polyacrylic acid or its salts, polyhydroxyethyl methacrylate, polyvinyl alcohol, polylactic acid, and polyglycolic acid, glycosaminoglycans such as hyaluronic acid and chondroitin sulfate, polysaccharides such as starch, glycogen, agarose, pectin, and cellulose, proteins such as collagen, gelatin, fibronectin, vitronectin, laminin, entactin, tenascin, thrombospondin, von Willebrand factor, osteopontin, fibrinogen, and Matrigel (registered trademark), and glycoproteins such as proteoglycans. The hydrogel can be placed at a desired position in the decellularized ECM using a syringe or the like.

[0030] The decellularized ECM of the present embodiment may be sterilized by a known method, such as sterilization with an antibiotic (penicillin, ampicillin, tetracycline, streptomycin, gentamicin, ampholycin B, etc.), autoclave sterilization, UV irradiation sterilization, gamma ray irradiation sterilization, ozone sterilization, ethylene oxide gas (EOG) sterilization, or a combination thereof.

[0031] <Hydroxyl Group-Containing Polymer (I)> The hydroxyl-containing polymer (I) of this embodiment has a group represented by the above formula (I). In formula (I), the carbon number of Z is preferably 3 to 6, and more preferably 3 to 5. The number of hydroxyl groups that Z has is preferably 2 or 3, and more preferably 2.

[0032] The hydroxyl-containing polymer (I) is not particularly limited as long as it is a polymer having a group represented by the above formula (I). The hydroxyl-containing polymer (I) may be a polyester compound, a polyether compound, a polyamide compound, a polyimide compound, a polyamideimide compound, a polyamic acid compound, a polyvinyl compound, or a combination thereof. The hydroxyl-containing polymer (I) may be a homopolymer or a copolymer. The group represented by formula (I) may be bonded to the end of the hydroxyl-containing polymer (I) or to a portion other than the end. When the hydroxyl-containing polymer (I) has a main chain and a graft chain, the group represented by formula (I) may be bonded to the main chain or to the graft chain. In addition, a natural polymer such as gelatin, hyaluronic acid, or alginic acid may be introduced with a group represented by formula (I) and used as the hydroxyl-containing polymer (I).

[0033] The solubility of the hydroxyl-containing polymer (I) in 100 ml of water at 25° C. is preferably 5 g or more, and more preferably 10 g or more. There is no particular upper limit to the solubility of the hydroxyl-containing polymer (I) in water at 25° C., and the hydroxyl-containing polymer (I) may be miscible with water in any ratio.

[0034] The hydroxyl-containing polymer (I) preferably contains 0.0001 mol / g or more of the group represented by formula (I), more preferably 0.001 mol / g or more, even more preferably 0.0025 mol / g or more, and even more preferably 0.005 mol / g or more, where the unit mol / g is the number of moles of the group represented by formula (I) per gram of the hydroxyl-containing polymer (I).

[0035] The hydroxyl-containing polymer (I) preferably contains a structural unit derived from a monomer having a group represented by formula (I) and an ethylenically unsaturated group (hereinafter also referred to as monomer (I)). The "structural unit derived from monomer (I)" refers not only to a structural unit obtained by polymerizing monomer (I), but also to a structural unit obtained by a method other than polymerizing monomer (I), as long as the structural unit has the same structure as the structural unit obtained by polymerizing monomer (I). For example, a structural unit obtained by deprotecting the hydroxyl group in the Z group of monomer (I) after polymerization of monomer (I) is the same structural unit as that obtained by polymerizing monomer (I), and is therefore included in the "structural unit derived from monomer (I)". In addition, when the Z group of monomer (I) has multiple hydroxyl groups, a monomer in which two of the hydroxyl groups form a cyclic ether structure by intramolecular dehydration is polymerized, and then the cyclic ether structure is hydrolyzed with an acid or the like to return to the hydroxyl groups. This structural unit has the same structure as when monomer (I) is polymerized, and is therefore included in the "structural unit derived from monomer (I)".

[0036] The monomer (I) is preferably a compound represented by the following formula (IA).

[0037] [ka] (In formula (IA), Z has the same meaning as Z in formula (I), and R represents a hydrogen atom or a methyl group.)

[0038] Z is preferably a group represented by the following formula (II): [ka] (In formula (II), R 1 is -CH(OH)CHOH or -CHOH, R 2 is a hydrogen atom or -CHOH, and R 3is a hydrogen atom or -CHOH, and * represents the bonding position of the group represented by formula (II).

[0039] As the monomer (I), glycerol mono(meth)acrylate is preferred.

[0040] The structural unit derived from the monomer (I) also includes a structural unit derived from a monomer that can generate a hydroxyl group by (co)polymerization and then treatment with an acid, such as the following monomer (IB):

[0041] [ka] (In formula (IB), R 11 represents a hydrogen atom or a methyl group, R 13 and R 14 each independently represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms.

[0042] When the monomer (IB) is polymerized and then treated with acid, the dioxolane ring is hydrolyzed, generating two hydroxyl groups in the structural unit.

[0043] The hydroxyl-containing polymer (I) may be a copolymer of the monomer (I) and another monomer, such as a compound having an ethylenically unsaturated group and an alkylene glycol group or a polyalkylene glycol group. Further, examples of other monomers include neutral hydrophilic monomers such as (meth)acrylamide, N-alkyl(meth)acrylamides (e.g., N,N-dimethyl(meth)acrylamide), N-vinylpyrrolidone, N-vinylpyrrolidinone, N-vinylacetamide, N-vinylformamide, hydroxyethyl(meth)acrylate, and hydroxypropyl(meth)acrylate; anionic hydrophilic monomers such as (meth)acrylic acid or a salt thereof, maleic acid or a salt thereof, fumaric acid or a salt thereof, itaconic acid or a salt thereof, (meth)acrylamidomethylpropanesulfonic acid or a salt thereof, vinylphosphonic acid or a salt thereof, and vinylbenzoic acid or a salt thereof; and cationic hydrophilic monomers such as 3-aminopropyl(meth)acrylamide (APMA), (meth)acrylamidopropyltrimethylammonium chloride (MAPTAC), and N,N-dimethylaminoethyl(meth)acrylate. Examples of other monomers include hydrophobic monomers such as methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, methoxyethyl (meth)acrylate, and styrene, and reactive group-containing monomers such as glycidyl (meth)acrylate, isopropenyl oxazoline, vinyl oxazoline, and maleic anhydride. The other monomers may be used alone or in combination of two or more. The content of the structural unit derived from the monomer having a carboxy group and an ethylenically unsaturated group in the hydroxyl group-containing polymer (I) may be less than 1 mass%, 0.8 mass% or less, or 0.5 mass% or less, based on the total amount of the hydroxyl group-containing polymer (I). The structural unit derived from the monomer having a carboxy group and an ethylenically unsaturated group may be a structural unit obtained by polymerizing the monomer, but may also be a structural unit obtained by a method other than polymerizing the monomer, so long as it has the same chemical structure (for example, a structural unit obtained by polymerizing a corresponding ester compound, hydrolyzing the ester group to give a carboxy group, etc.).

[0044] An example of the compound having an ethylenically unsaturated group and an alkylene glycol group or a polyalkylene glycol group is a compound represented by the following formula (III).

[0045] [ka]

[0046] In the above formula (III), A represents a hydrogen atom or an organic group having 1 to 20 carbon atoms, X represents -C(=O)-, -CH2-, -CH2CH2-, -CH2CH2CH2- or a single bond, Q represents an alkylene group having 2 to 20 carbon atoms, n represents a repeating unit of an alkylene oxide group and is a number of 1 to 200, k represents a hydrogen atom or an organic group having 1 to 20 carbon atoms which may have a substituent.

[0047] Above A and A k are each preferably a hydrogen atom or an organic group having 1 to 12 carbon atoms, more preferably a hydrogen atom or an organic group having 1 to 8 carbon atoms, and more preferably a hydrogen atom or an organic group having 1 to 4 carbon atoms. When the organic group has a substituent, it is more preferable that the number of carbon atoms including the substituent is within the above range. k It is even more preferable that each is a hydrogen atom or a methyl group.

[0048] The above Q is preferably an alkylene group having 2 to 5 carbon atoms, and more preferably an ethylene group, an n-propylene group, or an isopropylene group. Q may contain only one type of alkylene group, or may contain two or more types of alkylene groups. When Q contains an ethylene group, it is preferable that 50 to 100 mol % of the total alkylene glycol units in the polyalkylene glycol group are ethylene groups, more preferably 80 to 100 mol %, and more preferably 90 to 100 mol % are ethylene groups.

[0049] m may be the average number of moles added for all the compounds represented by formula (III). m is preferably 1 to 100, more preferably 5 to 80, and further preferably 10 to 60. When X is represented by -C(=O)-, examples of the compound include adducts of alkylene oxides having 1 to 100 carbon atoms to (meth)acrylic acid: esters of alkoxypolyalkylene glycols obtained by adding alkylene oxides having 1 to 100 carbon atoms to alkyl alcohols having 1 to 30 carbon atoms, such as methanol, ethanol, 2-propanol, and 1-butanol, with (meth)acrylic acid. When X is represented by -CH2-, -CH2CH2-, or -CH2CH2CH2-, examples of the compound include compounds having a structure in which 1 to 100 moles of alkylene oxide are added to an unsaturated alcohol such as allyl alcohol, methallyl alcohol, 2-buten-1-ol, 2-methyl-2-buten-1-ol, 3-methyl-3-buten-1-ol, 3-methyl-2-buten-1-ol, 2-methyl-3-buten-2-ol, or vinyl alcohol, and one or more of these may be used. Further, examples of the compound represented by formula (III) include polyalkylene oxide chain-containing (meth)acrylic acid esters such as 2-ethylhexyl carbitol (meth)acrylate, and alkoxyalkyl (meth)acrylic acid esters such as methoxybutyl (meth)acrylate, methoxyethyl (meth)acrylate, and ethoxybutyl (meth)acrylate.

[0050] The content of the structural unit derived from the monomer (I) in the hydroxyl-containing polymer (I) may be 1 to 100% by mass, or may be 5 to 100% by mass. When the hydroxyl-containing polymer (I) contains a structural unit derived from a compound having an ethylenically unsaturated group and an alkylene glycol group or a polyalkylene glycol group, the content of the structural unit may be 30 to 95% by mass based on the total amount of the hydroxyl-containing polymer (I).

[0051] As a method for producing the hydroxyl-containing polymer (I), for example, when the hydroxyl-containing polymer (I) has a structural unit derived from the monomer (I), a method of polymerizing a monomer composition containing the monomer (I) and, as an optional component, another monomer for copolymerization with the monomer (I) can be mentioned.

[0052] When the monomer composition is polymerized, a polymerization initiator can be used.

[0053] As the polymerization initiator, a radical polymerization initiator (particularly a thermal polymerization initiator) is preferable, and examples of the peroxide initiator include benzoyl peroxide, lauroyl peroxide, octanoyl peroxide, orthochlorobenzoyl peroxide, orthomethoxybenzoyl peroxide, diisopropyl peroxydicarbonate, cyclohexanone peroxide, t-hexylperoxy-2-ethylhexanoate (trade name: Perhexyl O (registered trademark)), 1,1-di(t-hexylperoxy)cyclohexane (trade name: Perhexa HC (registered trademark)), cumene hydroperoxide, t-butyl hydroperoxide, methyl ethyl ketone peroxide, and diisopropylbenzene hydroperoxide. Polymerization initiators include azo compound-based polymerization initiators such as 2,2'-azobisisobutyronitrile, 2,2'-azobis(2,4-dimethylvaleronitrile), 2,2'-azobis(2,3-dimethylbutyronitrile), 2,2'-azobis-(2-methylbutyronitrile), 2,2'-azobis(2,3,3-trimethylbutyronitrile), 2,2'-azobis(2-isopropylbutyronitrile), 1,1'-azobis(cyclohexane-1-carbonitrile), 2,2'-4-methoxy-2,4-dimethylvaleronitrile), 2-(carbamoylazo)isobutyronitrile, 4,4'-azobis(4-cyanovaleric acid), and dimethyl-2,2'-azobisisobutyrate. These may be used alone or in combination of two or more kinds.

[0054] The amount of the polymerization initiator used is not particularly limited, but is usually preferably 0.001 to 20 parts by mass, more preferably 0.01 to 10 parts by mass, per 100 parts by mass of the raw material monomers of the polymer (A).

[0055] The polymerization initiator may be added to the monomer composition all at once and then reacted, or may be added in two or more portions during the reaction (divided addition). In the case of divided addition, a portion of the polymerization initiator may be added to the monomer composition to start the reaction, and then the polymerization initiator may be intermittently added to the remaining monomer composition during the reaction.

[0056] The monomer composition may contain a solvent. That is, the monomer composition may be polymerized in the presence of a solvent. The solvent is not particularly limited, and may include water and organic solvents, but water is preferred. When the monomer contains a solvent, the content of the monomer in the monomer composition (content of monomer (I), or when other monomers are used, total amount of monomer (I) and other monomers) may be 0.1 to 50 mass%, 0.5 to 30 mass%, or 1 to 10 mass%. In this case, the hydroxyl group-containing polymer (I) is obtained as a solution of the hydroxyl group-containing polymer (I).

[0057] The weight average molecular weight of the hydroxyl group-containing polymer (I) is not particularly limited, but from the viewpoint of further increasing water solubility, it may be 5000 to 2000000. The weight average molecular weight can be measured by gel permeation chromatography (GPC).

[0058] <Method of manufacturing biomaterials and method of treating scaffolds> In the method for producing a biomaterial of the present embodiment, a scaffold containing decellularized ECM is treated with the above-mentioned hydroxyl-containing polymer (I). For example, a method for treating the scaffold may be to contact the surface of the scaffold with the hydroxyl-containing polymer (I).

[0059] The hydroxyl-containing polymer (I) may be contacted with the scaffold in the form of a solution (treatment liquid) in which the hydroxyl-containing polymer (I) is dissolved in a solvent. The solvent in the solution is preferably water or a mixed solvent of water and a hydrophilic solvent. In other words, the solution may be an aqueous solution. The proportion of water in the solvent in the aqueous solution is preferably 80% by mass or more, more preferably 90% by mass or more, and even more preferably 95% by mass or more.

[0060] The pH of the aqueous solution of this embodiment can be appropriately selected depending on the type of organ or tissue from which the decellularized ECM is derived, but is preferably 6.5 to 8.0, and more preferably 7.0 to 7.5. The aqueous solution of this embodiment may be one in which the hydroxyl-containing polymer (I) is dissolved in physiological saline.

[0061] The content of the hydroxyl-containing polymer (I) in the aqueous solution may be 0.01 to 50 mass%, 0.05 to 30 mass%, or 0.05 to 10 mass%, and the content of the solvent in the aqueous solution may be 50 mass% or more, 70 mass% or more, or 90 mass% or more.

[0062] The aqueous solution contains a buffer. The buffer is not particularly limited, and examples thereof include borate buffer, phosphate buffer, carbonate buffer, citrate buffer, acetate buffer, Tris buffer, etc. These buffers may be used alone or in any combination of two or more. Examples of borate buffer include boric acid, or borates such as alkali metal borate and alkaline earth metal borate. Examples of phosphate buffer include phosphoric acid, or phosphates such as alkali metal phosphate and alkaline earth metal phosphate. Examples of carbonate buffer include carbonic acid, or carbonates such as alkali metal carbonate and alkaline earth metal carbonate. Examples of citrate buffer include citric acid, or alkali metal citrate and alkaline earth metal citrate. In addition, hydrates of borates or phosphates may be used as borate buffer or phosphate buffer. More specific examples of the borate buffer include boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.); phosphate buffer includes phosphoric acid or a salt thereof (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, dipotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, etc.); carbonate buffer includes carbonic acid or a salt thereof (sodium hydrogen carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium hydrogen carbonate, magnesium carbonate, etc.); citrate buffer includes citric acid or a salt thereof (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.); acetate buffer includes acetic acid or a salt thereof (ammonium acetate, potassium acetate, calcium acetate, sodium acetate, etc.). Among these buffers, phosphate buffers (particularly a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate) are preferred.

[0063] The content of the buffering agent in the aqueous solution may be appropriately selected depending on the type of organ or organs that are used as the raw material for the decellularized ECM, the animal species, etc., and is not particularly limited, but based on the total volume of the aqueous solution, the total content of the buffering agent is 0.01 to 15 w / v%, preferably 0.05 to 10 w / v%, more preferably 0.1 to 7.5 w / v%, and particularly preferably 0.5 to 5 w / v%.

[0064] When the scaffold is treated using the treatment solution, for example, the scaffold may be immersed in the treatment solution or the treatment solution may be brought into contact with a desired position of the scaffold. The desired position includes a portion that comes into contact with blood during blood perfusion at the time of transplantation or after transplantation, for example, a portion of the decellularized ECM derived from a blood vessel (artery, vein, portal vein, capillary blood vessel, etc.). When the decellularized ECM has a portion derived from a blood vessel, a specific method of contacting the treatment solution includes injecting the treatment solution into the lumen of the portion derived from a blood vessel with a syringe or the like, or circulating the solution within the lumen of the portion derived from a blood vessel. Circulation may be performed by transporting the treatment solution with a pump or the like. The portion derived from a blood vessel of the decellularized ECM may have endothelial cells or the like engrafted thereon before being treated with the hydroxyl group-containing polymer (I). The surface of the scaffold may be modified by the hydroxyl group-containing polymer (I) through the above treatment. Furthermore, the above treatment may not only modify the surface, but also modify the interior of the scaffold by penetrating the hydroxyl group-containing polymer (I) into the interior.

[0065] The biomaterial produced by the production method of this embodiment can be used as a transplant material, an artificial organ, or a bioreactor, without any particular limitation. EXAMPLES

[0066] <Synthesis Example 1> In a 200 mL glass separable flask equipped with a thermometer, a gas inlet tube, a reflux condenser, and a stirrer, 10 g of glycerol monoacrylate (hereinafter referred to as GLMA) and 86 g of pure water were charged, and the temperature was raised to 97° C. while stirring under a nitrogen stream. Next, 1 g of a 0.5% by mass aqueous solution of azo-based initiator VA086 (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added to start polymerization. The start of polymerization was confirmed by a reflux state caused by polymerization heat, and while heating to maintain the reflux state, 1 g of a 0.5% by mass aqueous solution of VA086 was added 2 hours, 4 hours, and 6 hours after the start of polymerization. The reaction was completed 8 hours after the start of polymerization, and an aqueous solution of polyglycerol acrylate (hereinafter referred to as PGLMA) (solid content 10% by mass) was obtained.

[0067] <Synthesis Example 2> 60 g of pure water was charged into a 200 mL glass separable flask equipped with a thermometer, a gas inlet tube, a reflux condenser, and a stirrer, and the temperature was raised to 80° C. under stirring. Next, 3 g of glycerol monomethacrylate (hereinafter referred to as GLMMA), 36 g of Shin-Nakamura Chemical's methoxypolyethylene glycol #400 acrylate (hereinafter referred to as AM-90G), 20 g of 2 mass% sodium persulfate aqueous solution (hereinafter referred to as 2% NaPS), 0.76 g of 35 mass% sodium hydrogen sulfite aqueous solution (hereinafter referred to as 35% SBS), and 20 g of pure water were dropped into the pure water under stirring from separate dropping nozzles. The dropping times of each dropping liquid were 180 minutes for GLMMA and 180 minutes for AM-90G, 210 minutes for 2% NaPS, 180 minutes for 35% SBS, and 180 minutes for pure water. The above-mentioned droppings were all started at the same time, and the dropping speed was constant and continuously dropped. After the dropping was all completed, the reaction solution was kept at 80°C for another 30 minutes to mature and complete the polymerization. The obtained reaction solution was diluted with pure water to prepare an aqueous solution of a copolymer (a copolymer of GLMMA and AM-90G) with a solid content concentration of 10% by mass.

[0068] <Example 1> The liver removed from the rat was perfused with phosphate buffered saline to drain the remaining blood in the blood vessels. The rat liver was then frozen and stored at -80°C, and thawed when used. The decellularized ECM was prepared from the thawed rat liver by the perfusion method. The decellularized ECM was then sterilized by gamma irradiation. 20 ml of a solution in which a 10% by mass aqueous solution of PGLMA was diluted 100 times with phosphate buffered saline (PBS) was injected into the prepared rat decellularized ECM and incubated at 37°C for 1 hour to prepare a sample. 10 ml of blood was collected from a pig and immediately injected into the part of the sample derived from the blood vessels and left to stand for 10 minutes. After leaving it to stand, 30 ml of PBS was perfused to wash out the blood, and the remaining blood in the decellularized ECM and the formation of a blood clot were compared. The observation results are summarized in Table 1.

[0069] <Example 2> The same operation as in Example 1 was carried out, except that "20 ml of a solution obtained by diluting a 10% by mass aqueous solution of PGLMA 100 times with PBS" in Example 1 was changed to "20 ml of a solution obtained by diluting a 10% by mass aqueous solution of the copolymer in Synthesis Example 2 100 times with PBS." The observation results are summarized in Table 1.

[0070] <Comparative Example 1> The same operations as in Example 1 were carried out, except that "20 ml of a solution obtained by diluting a 10% by mass aqueous solution of PGLMA 100 times with PBS" in Example 1 was changed to "20 ml of PBS." The observation results are summarized in Table 1.

[0071] <Comparative Example 2> The same operations as in Example 1 were carried out except that "20 ml of a solution obtained by diluting a 10% by mass aqueous solution of PGLMA 100 times with PBS" was changed to "20 ml of a solution obtained by diluting a 10% by mass aqueous solution of polyvinylpyrrolidone (PVP) 10 times with PBS". The observation results are summarized in Table 1. Polyvinylpyrrolidone is a polymer that is frequently used as a biocompatible material.

[0072] [Table 1]

[0073] <Example 3> A decellularized ECM of a porcine liver was prepared by carrying out the same method as in Example 1 on a liver extracted from a pig. The prepared decellularized ECM was subjected to gamma ray sterilization, and recellularization was carried out to prepare a recellularized sample. An artificial blood vessel was connected to each of the portal vein and vein-derived portions of the prepared sample, and a treatment liquid was transferred through the artificial blood vessel with a pump to circulate within the sample. The treatment liquid was a 100-fold dilution of an aqueous solution of PGLMA (solid content 10% by mass) of Synthesis Example 1 with physiological saline. The portal vein and vein of the treated sample were anastomosed side-to-side to the portal vein and vein of a donor pig, and blood was reperfused into the sample. Angiography was performed 2 hours after the start of reperfusion, confirming blood flow within the sample, and no thrombus was observed.

Claims

1. A method for producing a biomaterial, comprising a step of treating a scaffold containing a decellularized extracellular matrix with a hydroxyl-containing polymer having a structural unit derived from glycerol mono(meth)acrylate.

2. The method for producing a biomaterial according to claim 1 , wherein the scaffold comprises cells engrafted on the decellularized extracellular matrix.

3. The method for producing a biomaterial according to claim 1 or 2, further comprising the step of recellularizing the treated scaffold.

4. The method for producing a biomaterial according to any one of claims 1 to 3, wherein the decellularized extracellular matrix is ​​derived from an organ or a blood vessel.

5. The method for producing a biomaterial according to any one of claims 1 to 4, wherein the decellularized extracellular matrix is ​​derived from the liver or a part of the liver.

6. The method for producing a biomaterial according to any one of claims 1 to 5, wherein the treatment is performed with a solution containing the hydroxyl group-containing polymer.

7. The method for producing a biomaterial according to claim 6, wherein the decellularized extracellular matrix has a portion derived from a blood vessel, and the treatment is carried out by injecting the solution into the lumen of the portion derived from a blood vessel or circulating the solution within the lumen of the portion derived from a blood vessel.

8. 1. A method of treating a scaffold, comprising the steps of: A method comprising the step of treating a scaffold comprising a decellularized extracellular matrix with a hydroxyl-containing polymer having structural units derived from glycerol mono(meth)acrylate.

9. A treatment solution for treating a scaffold comprising a decellularized extracellular matrix, comprising: A treatment liquid comprising a hydroxyl group-containing polymer having a structural unit derived from glycerol mono(meth)acrylate.

10. The treatment solution according to claim 9, further comprising a buffer.

Citation Information

Patent Citations

  • Recellularization methods for tissues or organs to improve transplantability

    JP2013536738A

  • Bioengineered allogeneic blood vessels

    JP2016144470A

  • Biocompatible medical material

    JP2018178072A

  • Fouling restraint function imparting agent

    JP2019042689A

  • Biological inactivator for biocompatible material surface treatment, bioinert material, and method for producing bioinert material

    WO2018186502A1